Physician profile
Agustin Ramirez
NPI 1982963740
$12,644.31
in general payments reported to CMS, 2019-2025
58 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $1,512 · 2021: $1,843 · 2022: $1,775 · 2023: $1,975 · 2024: $1,854 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,689.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,575.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,983.22 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $686.26 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $684.44 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $595.12 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $535.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $521.76 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $490.06 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $463.59 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $341.52 | 2020-2022 | |
| Novo Nordisk INC | $337.84 | 2019-2025 | Rybelsus, Ozempic |
| Lundbeck LLC | $254.77 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $228.05 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.14 | 2021-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $199.40 | 2022-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agustin Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.